INO Hits New High, APYX Expands Footprint, TBIO/SNY To Begin COVID-19 Vaccine Trial In Q4

Today's Daily Dose brings you news about the expanding footprint of Apyx Medical's Helium Plasma Technology products; Inovio securing a $71 million funding from the U.S. Department of Defense for its COVID-19 vaccine delivery systems and Myovant's positive results from its second phase III trial of Relugolix combination therapy in women with pain associated with endometriosis, among others.